FierceBiotech

Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea

SOUTH SAN FRANCISCO, Calif., April 10 /PRNewswire/ -- Napo Pharmaceuticals, Inc., (LSE: NAPL and NAPU) is pleased to announce the positive results of a successfully completed Phase 2 trial for CRO-ID ...
FiercePharma

Napo Terminates Glenmark Pharmaceuticals for Failure to Commercially Develop Crofelemer

SAN FRANCISCO--(BUSINESS WIRE)--Napo Pharmaceuticals, Inc. ("Napo") announced today that it has terminated its Collaboration Agreement with Glenmark Pharmaceuticals Ltd. ("Glenmark"), dated July 2, ...

Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts

SAN FRANCISCO, CA / ACCESS Newswire / January 14, 2026 /Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, ...
FierceBiotech

Press Release: Napo Obtains IRB Approval For Phase 3 Clinical Trial Protocol For Crofelemer

Napo Obtains IRB Approval For Phase 3 Clinical Trial Protocol For Crofelemer In HIV/AIDS Diarrhea Assessment Napo Pharmaceuticals, Inc. announces today that it has received approval from the principal ...
Yahoo Finance

Jaguar Health Subsidiary Napo Pharmaceuticals Signs License Agreement with its Italian Subsidiary, Napo EU S.p.A., to Develop and Commercialize Crofelemer and Lechlemer in Europe

SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2021 / Napo Pharmaceuticals, Inc. (Napo), the wholly owned US subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX), today announced the signing of a license ...